Scarica l'app Stockscreener
12.97
0.61%
-0.08
Dopo l'orario di chiusura:
13.14
0.17
+1.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Immunic Inc Borsa (IMUX) Ultime notizie
Wolfe Research initiated coverage on Immunic - Quantisnow
IMUX Maintained by B. Riley Securities -- Price Target Lowered t - GuruFocus
Immunic (IMUX) Price Target Reduced by B. Riley Analyst - GuruFocus
B. Riley Securities Maintains Immunic(IMUX.US) With Buy Rating, Cuts Target Price to $27 - Moomoo
B. Riley Adjusts Price Target on Immunic to $27 From $40, Maintains Buy Rating - Moomoo
Wolfe Research initiates Immunic stock with outperform rating - Investing.com
Wolfe Research initiates Immunic stock with outperform rating By Investing.com - Investing.com Canada
Immunic Appoints New Chair of Board - Intellectia AI
IMMUNIC (IMUX) director Michael W. Bonney listed as insider in Form 3 filing - Stock Titan
Immunic Appoints Michael W. Bonney as Board Chair to Guide Late-Stage MS Therapy Development and Commercialization - Minichart
Immunic names Michael Bonney as board chair By Investing.com - Investing.com South Africa
Immunic appoints Michael Bonney as chairman - The Pharma Letter
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout - Yahoo Finance
Immunic Appoints New Chair of Board of Directors - Intellectia AI
Immunic Appoints Michael Bonney as Board Chair - TipRanks
Immunic Names Michael Bonney as Board Chair - Moomoo
Biotech veteran Michael Bonney becomes Immunic (NASDAQ: IMUX) chair - Stock Titan
Immunic names Michael Bonney as board chair - Investing.com
Immunic appoints seasoned biopharmaceutical executive Michael W. Bonney as chair of the board of directors - marketscreener.com
Press Release: Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors - Moomoo
Is Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Immunic stock (US45256V1061): Q1 loss widens as short interest collapses - AD HOC NEWS
Alyeska discloses 6.33M-share stake in Immunic (NASDAQ: IMUX) - Stock Titan
Immunic, Inc.Common Stock (NQ: IMUX - FinancialContent
Immunic announces 1-for-10 reverse stock split - MSN
A Quick Look at Today's Ratings for Immunic(IMUX.US), With a Forecast Between $19 to $56 - Moomoo
IMMUNIC (IMUX) amendment shows 683 Capital exit filing and 3.4% beneficial stake - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Immunic (IMUX), Tenon Medical, Inc. (TNON) - The Globe and Mail
Number of shareholders of Immunic, Inc. – NASDAQ:IMUX - TradingView
Roth MKM Maintains Immunic(IMUX.US) With Buy Rating, Cuts Target Price to $19 - Moomoo
Number of shareholders of Immunic, Inc. – FWB:10V - TradingView
H.C. Wainwright reiterates Immunic stock rating citing trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Immunic stock rating citing trial progress - Investing.com UK
Immunic stock (US45256V1061): Q1 earnings and Phase 3 trial preparations - AD HOC NEWS
Immunic (IMUX) Q1 2026 Earnings: EPS N/A, Revenue N/A -- Is the - GuruFocus
Immunic Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Immunic (IMUX) Prepares for Pivotal Phase 3 Trials with Strength - GuruFocus
Immunic Releases Q1 2026 Financial Results - AlphaStreet
Immunic, Inc. Reports Q1 2026 Financial Results, Advances Phase 3 Trials for Vidofludimus Calcium in Multiple Sclerosis, and Raises $200M in Private Placement - Minichart
Immunic advances Phase 3 MS program, eyes topline data by year-end - Yahoo Finance
Immunic CEO on Q1 highlights, new appointments and upcoming milestones - Proactive financial news
Immunic, Inc. Q1 2026 Financial Results and Clinical Progress in Neurologic Disease Therapies - Minichart
IMUX: Vidofludimus calcium shows strong efficacy and safety in MS, targeting a $3-7B market - TradingView
Immunic reports Q1 2026 net loss $32.6M, cash $186.6M after $200M private placement - TradingView
IMMUNIC ($IMUX) Releases Q1 2026 Earnings - Quiver Quantitative
IMMUNIC, INC. 1Q 2026: Revenue $0 Net loss $32.6M — 10-Q Summary - TradingView
Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Immunic (NASDAQ: IMUX) boosts cash with $200M warrant deal amid Q1 loss - Stock Titan
Immunic: Q1 Earnings Snapshot - marketscreener.com
Press Release: Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):